Lauren E Himmel (Lauren Himmel)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 5

Top Topics

Rheumatoid Arthritis Patients

Top Venues

Science advances

Toxicologic pathology

Nature biomedical engineering

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Tracey L Papenfuss, Lauren E Himmel, C Frieke Kuper, Sunish Mohanan, Johannes Harleman, Susan A Elmore
Toxicologic Pathology Forum: Considerations Regarding Determination of Adversity for Immunopathology Findings in Nonclinical Toxicology Studies with Immune-Modulating Therapeutics. Toxicologic pathology (2023)
Sean K Bedingfield, Juan M Colazo, Fang Yu, Danielle D Liu, Meredith A Jackson, Lauren E Himmel, Hongsik Cho, Leslie J Crofford, Karen A Hasty, Craig L Duvall
Amelioration of post-traumatic osteoarthritis via nanoparticle depots delivering small interfering RNA to damaged cartilage. Nature biomedical engineering 5 (9) (2021)
Vera M Todd, Lawrence A Vecchi, Miranda E Clements, Katherine P Snow, Cayla D Ontko, Lauren E Himmel, Christopher Pinelli, Marjan Rafat, Rachelle W Johnson
Hypoxia inducible factor signaling in breast tumors controls spontaneous tumor dissemination in a site-specific manner. Communications biology 4 (1) (2021)
Spencer C Wei, Wouter C Meijers, Margaret L Axelrod, Nana-Ama A S Anang, Elles M Screever, Elizabeth C Wescott, Douglas B Johnson, Elizabeth Whitley, Lorenz Lehmann, Pierre-Yves Courand, James J Mancuso, Lauren E Himmel, Benedicte Lebrun-Vignes, Matthew J Wleklinski, Bjorn C Knollmann, Jayashree Srinivasan, Yu Li, Oluwatomisin T Atolagbe, Xiayu Rao, Yang Zhao, Jing Wang, Lauren I R Ehrlich, Padmanee Sharma, Joe-Elie Salem, Justin M Balko, Javid J Moslehi, James P Allison
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. Cancer discovery 11 (3) (2020)
Nidhi Jyotsana, Zhenjiang Zhang, Lauren E Himmel, Fang Yu, Michael R King
Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast cancer metastasis following tumor resection. Science advances 5 (7) (2019)